Hancock Jaffe Laboratories

General Information


We are a development stage medical device company developing biologic based solutions that are designed to be life-enhancing for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease, or ESRD. Each product candidate we are developing is designed to allow vascular and cardiothoracic surgeons to achieve effectiveness while improving current procedures and healthcare for a variety of patients. We are in the process of developing and obtaining U.S. Food and Drug Administration, or FDA, approval for the following three products: the Bioprosthetic Heart Valve, the Bioprosthetic Coronary Artery Bypass Graft, which we refer to as CoreoGraft, and the Bioprosthetic Venous Valve, which we refer to as the VenoValve.

Employees: 12
Founded: 1999
Contact Information
Address 70 Doppler, Irvine, California, 92618, US
Phone Number (949) 261-2900
Web Address http://www.hancockjaffe.com.
View Prospectus: Hancock Jaffe Laboratories
Financial Information
Market Cap $71.3mil
Revenues $0.3 mil (last 12 months)
Net Income $-11.9 mil (last 12 months)
IPO Profile
Symbol HJLI
Exchange NASDAQ
Shares (millions): 1.5
Price range $5.00 - $5.00
Est. $ Volume $7.5 mil
Manager / Joint Managers Network 1 Financial Securities
CO-Managers ViewTrade Securities
Expected To Trade: 5/31/2018
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change